OPNT · Opiant Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Revenue | $29.63M | - | - | $15.55M | $18.45M | $9.90M |
| Cost of Revenue | - | - | $13.72M | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $16.83M | $9.24M | $9.08M | $4.86M | $3.17M | $1.75M |
| SG&A | $12.15M | $11.74M | $12.20M | $11.26M | $6.53M | $15.57M |
| Total Operating Expenses | $42.63M | $31.87M | $29.61M | $17.43M | $11.35M | $17.64M |
| D&A | $94.5K | $123.7K | $60.8K | $2.6K | $5.1K | $2.4K |
| Operating Income | $5.16M | ($2.24M) | $10.91M | ($1.88M) | $7.09M | ($7.74M) |
| Interest Expense | $2.13M | $131.0K | - | - | - | - |
| Income Tax | $24.3K | ($425.7K) | ($177.2K) | $797.0K | $550.5K | $0 |
| Net Income | $3.01M | ($1.86M) | $11.59M | ($2.61M) | $6.58M | ($7.81M) |
| EPS - Basic | $0.68 | ($0.44) | $2.88 | ($7.10) | ($4.09) | - |
| EPS - Diluted | $0.51 | ($0.44) | $2.17 | ($7.10) | ($4.09) | - |
Balance Sheet
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $37.85M | $48.25M | $30.98M | $24.61M | $8.12M | $1.48M |
| Accounts Receivable | $13.33M | $8.91M | $7.22M | $4.49M | $11.70M | $0 |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - |
| Current Assets | $69.16M | $59.10M | $39.25M | $29.37M | $20.75M | $1.86M |
| Total Assets | $70.43M | $60.61M | $40.28M | $29.39M | $20.77M | $1.88M |
| Current Liabilities | $6.85M | $6.42M | $5.61M | $9.83M | $5.66M | $4.24M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $23.59M | $25.12M | $5.86M | $12.53M | $7.77M | $6.59M |
| Stockholders' Equity | $46.84M | $35.49M | $34.42M | $16.86M | $13.00M | ($4.70M) |
| Retained Earnings | ($61.68M) | ($64.69M) | ($62.83M) | ($74.42M) | ($53.23M) | ($61.19M) |
Cash Flow
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.93M | ($2.03M) | $4.06M | ($523.0K) | ($915.3K) | ($915.3K) |
| Investing Cash Flow | ($15.01M) | ($50.9K) | ($302.5K) | - | ($7.5K) | ($7.5K) |
| Financing Cash Flow | $2.72M | $19.37M | $2.61M | $17.02M | $1.97M | $1.97M |
| CapEx | $0 | $50.9K | $302.5K | - | $0 | $7.5K |
| Free Cash Flow | $1.93M | ($2.08M) | $3.76M | - | ($915.3K) | ($922.8K) |
Ratios
| Metric | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | 17.4% | - | - | -12.1% | 38.5% | -78.2% |
| EBITDA margin | 17.7% | - | - | -12.1% | 38.5% | -78.2% |
| Net margin | 10.2% | - | - | -16.8% | 35.7% | -79.0% |
| Free cash flow margin | 6.5% | - | - | - | -5.0% | -9.3% |
| FCF / Net income | 0.64 | 1.12 | 0.32 | - | -0.14 | 0.12 |
| R&D / Revenue | 56.8% | - | - | 31.2% | 17.2% | 17.7% |
| SG&A / Revenue | 41.0% | - | - | 72.4% | 35.4% | 157.3% |
| Effective tax rate | 0.8% | - | -1.6% | - | 7.7% | - |
| Return on assets | 4.3% | -3.1% | 28.8% | -8.9% | 31.7% | -415.2% |
| Return on equity | 6.4% | -5.2% | 33.7% | -15.5% | 50.6% | 166.1% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 10.10 | 9.21 | 7.00 | 2.99 | 3.67 | 0.44 |
| Quick ratio | 10.10 | 9.21 | 7.00 | 2.99 | 3.67 | 0.44 |
| Cash ratio | 5.53 | 7.52 | 5.52 | 2.50 | 1.43 | 0.35 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | 2.4x | -17.1x | - | - | - | - |
| Equity multiplier | 1.50 | 1.71 | 1.17 | 1.74 | 1.60 | -0.40 |
| Liabilities / Assets | 0.33 | 0.41 | 0.15 | 0.43 | 0.37 | 3.50 |
| Efficiency | ||||||
| Asset turnover | 0.42 | - | - | 0.53 | 0.89 | 5.26 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 164d | - | - | 105d | 231d | 0d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | -15.7% | 86.4% | 538.6% |
| Revenue CAGR (3y) | 24.0% | - | - | 115.7% | - | - |
| Revenue CAGR (5y) | 24.5% | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | - | - | - | -12.2% |
| Net income growth (YoY) | - | - | - | - | - | -11.0% |
| EPS growth (YoY) | - | - | - | -73.6% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | 0.8% | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 32.0% | 3.1% | 104.1% | 29.7% | - | 43.9% |
Stability scores
Altman Z′
FY 2021 · bankruptcy risk
1.37
Grey zone
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2021 · 9-point quality
4/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing OPIANT PHARMACEUTICALS against the 5 most active filers in the same SIC group.